Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 19 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 10913790

    Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  2. US 10905709

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  3. US 10907160

    Methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  4. US 10894966

    Virus-based expression vectors and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 19, 2021 · Expires Jan 14, 2041

    granted
  5. WO 2021005497

    ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIUM POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA DÉPRESSION CORTICALE ENVAHISSANTE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 14, 2021 · Expires Jan 9, 2041

    granted
  6. US 10883104

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  7. US 10876118

    Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell

    The Regents of the University of California · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  8. US 10875903

    Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  9. US 10870837

    Fusion proteins comprising enzyme replacement therapy enzymes

    DENALI THERAPEUTICS INC. · Granted Dec 22, 2020 · Expires Dec 17, 2040

    granted
  10. US 2020384125

    GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION

    CRISPR THERAPEUTICS AG [CH] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted
  11. US 10858658

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  12. US 10857231

    Formulations of VEG antagonist fusion proteins and method of manufacturing them

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  13. US 10857106

    Methods and products for treating and/or delaying onset of dysplastic lesions

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  14. US 10849885

    Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

    PTC THERAPEUTICS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  15. US 10850011

    Hydrogel membrane for adhesion prevention

    The Board of Regents of the University of Texas · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  16. US 10849878

    Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon

    OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM” · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  17. US 10851358

    Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome

    Precision BioSciences, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  18. US 10849917

    Antisense-induced exon exclusion in type VII collagen

    Sarepta Therapeutics, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  19. US 10844098

    Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein

    Institute of Biotechnology, Academy of Military Medical Sciences, China · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  20. US 10844357

    Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines

    The Board of Regents for Oklahoma State University · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  21. US 10844129

    Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids

    Inhibrx, Inc. · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  22. US 10842823

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  23. US 10837016

    Modulation of huntingtin expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted
  24. US 10829770

    Fusion proteins containing luciferase and a polypeptide of interest

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted